RPL22 and cancer: Other dMMR/MSI‐associated immune escape mutations that varied in frequency between cancer types included RPL22, which was enriched in EC, and the antigen processing and presentation pathway components B2M, NLRC5, TAP2, and HLA‐B, which were more commonly disrupted in CRC.